Richard Stein's most recent trade in BioXcel Therapeutics Inc was a trade of 70,000 Restricted Stock Units done . Disclosure was reported to the exchange on Jan. 1, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2026 | 70,000 | 70,282 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2025 | 35 | 6,577 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2025 | 35 | 282 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2025 | 33 | 130 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2025 | 33 | 6,542 (0%) | 0% | - | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 371.23 per share. | 05 Dec 2025 | 2,450 | 10,379 (0%) | 0% | 371.2 | 909,514 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 370.62 per share. | 05 Dec 2025 | 1,040 | 12,829 (0%) | 0% | 370.6 | 385,445 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 372.20 per share. | 05 Dec 2025 | 779 | 9,600 (0%) | 0% | 372.2 | 289,944 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 367.06 per share. | 05 Dec 2025 | 332 | 14,052 (0%) | 0% | 367.1 | 121,864 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 05 Dec 2025 | 275 | 16,812 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 373.20 per share. | 05 Dec 2025 | 274 | 9,326 (0%) | 0% | 373.2 | 102,257 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 368.63 per share. | 05 Dec 2025 | 183 | 13,869 (0%) | 0% | 368.6 | 67,459 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2025 | 35 | 317 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2025 | 35 | 6,509 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2025 | 33 | 6,474 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2025 | 33 | 163 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2025 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2025 | 4,375 | 5,816 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2025 | 625 | 0 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jul 2025 | 625 | 6,441 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 35 | 352 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 35 | 1,441 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 33 | 1,406 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2025 | 33 | 196 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 387 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 34 | 1,373 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 1,339 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2025 | 31 | 229 | - | - | Restricted Stock Units | |
| Citizens Financial Group | Richard Stein | Chief Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 14,556 | 99,344 (0%) | 0% | 0 | Common Stock | |
| Citizens Financial Group | Richard Stein | Chief Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 45.77 per share. | 01 Mar 2025 | 10,461 | 88,883 (0%) | 0% | 45.8 | 478,800 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 7,836 | 29,232 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2025 | 6,971 | 31,439 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 357.36 per share. | 25 Feb 2025 | 4,764 | 24,468 (0%) | 0% | 357.4 | 1,702,463 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Chief Executive Officer | Sale of securities on an exchange or to another person at price $ 373.79 per share. | 18 Feb 2025 | 3,500 | 21,396 (0%) | 0% | 373.8 | 1,308,265 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 5,064 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 562 | 21,362 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 20,800 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2024 | 521 | 2,606 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 372 | 20,932 (0%) | 0% | 0.4 | 133 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.36 per share. | 14 Dec 2024 | 205 | 21,157 (0%) | 0% | 0.4 | 74 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Sep 2024 | 21,250 | 27,454 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.55 per share. | 17 Sep 2024 | 7,175 | 20,279 (0%) | 0% | 0.5 | 3,946 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 6,560 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 563 | 5,625 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 5,997 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2024 | 521 | 3,127 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 0.69 per share. | 14 Sep 2024 | 356 | 6,204 (0%) | 0% | 0.7 | 246 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 1,875 | 1,875 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jul 2024 | 625 | 625 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Jun 2024 | 125,000 | 125,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 5,848 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 562 | 6,188 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 5,286 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2024 | 521 | 3,648 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.26 per share. | 14 Jun 2024 | 372 | 5,476 (0%) | 0% | 1.3 | 470 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 6,750 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 2,250 | 5,834 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.64 per share. | 14 Mar 2024 | 1,069 | 4,765 (0%) | 0% | 2.6 | 2,817 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 4,169 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2024 | 521 | 3,584 (0%) | 0% | - | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2024 | 12,776 | 29,690 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Steinmeier Richard | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 263.36 per share. | 25 Feb 2024 | 7,397 | 22,293 (0%) | 0% | 263.4 | 1,948,074 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2024 | 2,603 | 24,896 (0%) | 0% | 0 | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 3,063 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Steinhart Richard I. | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 521 | 4,690 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 5,211 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2023 | 521 | 2,542 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 5,732 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Jun 2023 | 521 | 2,021 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 14 May 2023 | 5,000 | 1,500 (0%) | 0% | 27.2 | 135,864 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 0 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 May 2023 | 5,000 | 6,500 (0%) | 0% | - | Common Stock | |
| Liberty Resources Acquisition | Garry Richard Stein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 30,000 | 40,000 | - | - | Class B Common Stock | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 9,000 | 9,000 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 6,253 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.50 per share. | 14 Mar 2023 | 2,084 | 1,500 (0%) | 0% | 19.5 | 40,638 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 2,084 | 3,584 (0%) | 0% | - | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 12,396 | 32,737 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.30 per share. | 25 Feb 2023 | 7,379 | 25,358 (0%) | 0% | 247.3 | 1,824,827 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 1,856 | 27,214 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.95 per share. | 16 Feb 2023 | 723 | 44,939 (0%) | 0% | 37.0 | 26,715 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 36.66 per share. | 16 Feb 2023 | 722 | 45,662 (0%) | 0% | 36.7 | 26,469 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 11,439 | 11,439 | - | - | Stock Appreciation Rights | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 8,092 | 46,384 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.17 per share. | 12 Feb 2023 | 1,501 | 38,292 (0%) | 0% | 37.2 | 55,792 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.24 per share. | 06 Feb 2023 | 2,362 | 39,793 (0%) | 0% | 37.2 | 87,961 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 223.79 per share. | 07 Sep 2022 | 3,737 | 20,341 (0%) | 0% | 223.8 | 836,303 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.53 per share. | 04 Aug 2022 | 7,355 | 31,433 (0%) | 0% | 77.5 | 570,233 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Aug 2022 | 7,355 | 0 | - | - | Option to purchase Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Sale of securities on an exchange or to another person at price $ 216.64 per share. | 04 Aug 2022 | 7,355 | 24,078 (0%) | 0% | 216.6 | 1,593,387 | Common Stock |
| Fifth Third Bancorp | Richard Stein | EVP | Payment of exercise price or tax liability using portion of securities received from the company at price $ 37.00 per share. | 17 May 2022 | 409 | 42,155 (0%) | 0% | 37 | 15,133 | Common Stock |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Senior VP and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2022 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| Atossa Therapeutics Inc | Richard I. Steinhart | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 May 2022 | 50,000 | 500,000 | - | - | Stock Option (right to buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 33,350 | 33,350 | - | - | Stock Option (Right to Buy) | |
| BioXcel Therapeutics Inc | Richard I. Steinhart | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2022 | 8,337 | 8,337 | - | - | Restricted Stock Units | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 6,534 | 25,700 (0%) | 0% | 0 | Common Stock | |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 182.73 per share. | 25 Feb 2022 | 4,234 | 21,466 (0%) | 0% | 182.7 | 773,679 | Common Stock |
| LPL Fin Holdings Inc | Richard Steinmeier | Managing Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2022 | 2,612 | 24,078 (0%) | 0% | 0 | Common Stock | |
| Fifth Third Bancorp | Richard Stein | EVP | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 10,942 | 10,942 | - | - | Stock Appreciation Rights |